HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Child-resistant packaging

This article was originally published in The Rose Sheet

Executive Summary

Consumer Product Safety Commission forwards a briefing package to its commissioners on changes to the adult component of the child- resistant package test protocol to "determine whether public comment is warranted." The commissioners are expected to vote following a Feb. 3 CPSC-sponsored public meeting to discuss the changes. The changes include dividing the 60-75 year age group into three groups; distributing the participants within the three groups and weighting the groups to minimize variability; and developing a sequential test scheme. The briefing package recommends a 30-day comment period. A final rule is scheduled to be presented to the Commission in the fourth quarter of fiscal 1994, CPSC says. CPSC's initial proposal to amend the requirement for CRPs was issued in October 1990

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS000046

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel